Rare diseases
Investigational molecules
Locations
1 Broadway Floor 14th, 02142-1187, United States
Clinical research in advanced ALK-positive NSCLC includes treatment-naïve disease and settings with ALK resistance mutations, with attention to patients whose tumors are driven by ALK rearrangements or activating alterations.
Related work also extends to other solid tumors carrying ALK alterations.
Nuvalent Inc. runs clinical trials in conditions such as Non-small cell lung cancer, Neoplasm, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Austria
BelgiumBelgiumIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
